A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with first-line HER2-positive recurrent or metastatic breast cancer.

Trial Details

NCT ID
NCT07518173
Phase
PHASE3
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • BL-M07D1
  • Pertuzumab
  • Trastuzumab
  • Docetaxel
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Voluntarily sign the informed consent form and comply with the protocol requirements;
  • Female patients aged ≥18 and ≤75 years at the time of signing the informed consent form;
  • Expected survival time ≥12 weeks;
  • Patients with histologically or cytologically confirmed, previously untreated, unresectable recurrent or metastatic HER2-positive breast cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →